Kymera Therapeutics
Presence
Kymera Therapeutics is one of the...
Kymera Therapeutics is a company listed under the stock ticker KYMR (US).
Executives
View the org chart displaying its 27 main executives
Most searched biographies at Kymera Therapeutics
- Nello Mainolfi, Director, President and Chief Executive Officer
- Gorjan Hrustanovic, Director
- Joanna Horobin, Director
Create your alert
to follow the executive moves at Kymera Therapeutics.
Biotechnology
Kymera Therapeutics has 2,284 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Enlaza Therapeutics has just announced a $100 Million fundraising (posted on May 2 2024).
- Endeavor BioMedicines has just announced a $132 Million fundraising (posted on April 25 2024).
- Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
Popular contacts in Biotechnology
News
Press releases by Kymera Therapeutics
- Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine | Kymera Therapeutics, Inc.
- Press Releases | Kymera Therapeutics, Inc.
- Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma | Kymera Therap
- Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma | Kymera Therapeutics, Inc.
- Kymera Therapeutics to Participate in Upcoming September Investor Conferences | Kymera Therapeutics, Inc.
- Kymera Therapeutics to Report Second Quarter 2022 Results on August 9 | Kymera Therapeutics, Inc.
- Press Releases | Kymera Therapeutics, Inc.
- Press Releases | Kymera Therapeutics, Inc.
- Kymera Therapeutics Strengthens Board of Directors with Appointment of People and Business Leader Leigh Morgan | Kymera Therapeutics, Inc.
- Kymera Therapeutics Doses First Patients in Phase 1 Oncology Trials of STAT3 and IRAKIMiD Degraders KT-333 and KT-413 | Kymera Therapeutics, Inc.
- View more press releases Close
Social media about Kymera Therapeutics
- Kymera Therapeutics on Wikipedia, Google News & Yahoo Finance
- Kymera Therapeutics on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Nello Mainolfi 
Call Kymera Therapeutics at +1 857...
